BioCryst extends former CFO Anthony Doyle's consulting agreement through Dec 31, 2025

BIOCRYST PHARMACEUTICALS INC

Consulting Agreement extended from original end date to December 31, 2025; after that, month-to-month with 30-day notice.
Mr. Doyle provides transition services related to CFO succession at $450/hour; all other terms unchanged.
Original agreement effective April 9, 2025; extension announced on May 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.